Category: Stock Market

Commonwealth Bank of Australia (ASX: CBA) shares have been incredibly resilient so far this year.

After posting an unexpectedly positive half-year result in February this year, the banking giant’s shares jumped over 12%, and they’ve remained relatively consistent ever since.

At the time of writing on Tuesday afternoon, CBA shares are up 0.3% to $173.60. 

For the year to date, the shares are nearly 8% higher, and they’re up 6.6% on this time last year.

The gains go even further back, too.

CBA shares have risen mostly consistently since joining the ASX back in 1999.

How many shares could I have bought with $10,000 five years ago?

On this day five years ago, CBA shares were trading at $89.04 each. That means that $10,000 invested in CBA shares five years ago would have bought 112 shares.

What would that investment be worth now?

CBA shares have increased 95% over the past five years. That means that $10,000 invested in April 2021 would be worth $19,500 today.

And how many CBA shares would I get with the same $10,000 investment today?

While a $10,000 investment would have bought 112 shares in April 2021, today it would only buy 57 shares.

Are CBA shares still a buy today?

Not according to the experts. Analysts widely comment that the bank’s share price is overvalued relative to its peers, and that its bumper price tag isn’t supported by its business fundamentals. 

Brokers are mostly bearish on the outlook for CBA shares, with consensus of a steep share price downturn ahead.

TradingView data shows that 14 out of 16 analysts have a sell or strong sell rating on the stock. Another two rate CBA shares as a hold.

The average target price is $129.98, which implies a 25% downside at the time of writing. But some think the share price could crash 48% to just $90 within the next 12 months.

Are CBA shares worth buying for passive income?

While the 12-month outlook for CBA shares doesn’t look too positive, and a sharp correction is expected ahead, it’s worth remembering that the banking giant is a classic defensive stock. 

This means it is able to remain stable in times of economic crisis. Because of this, it generally has strong and consistent operational performance and earnings, even when markets are mostly weak.

Also, the bank is huge, dominant, and highly profitable, which means investors are struggling to see it as anything other than a safe haven during times of volatility. And so far in 2026, the sharemarket has been very volatile.

The best part is that because CBA is generally stable and defensive in nature, it is able to pay a reliable passive income to investors. 

CBA has paid dividends twice per year consistently since 2006. The bank last paid a fully-franked dividend of $2.35 per share to investors in late March.

The post 5 years ago, $10,000 bought 112 CBA shares. How many would it buy now? appeared first on The Motley Fool Australia.

More reading

• Experts name 1 ASX bank share to buy and 2 to sell       
• Which of the big four bank shares has the most upside?
• Buy, hold, sell: Macquarie, Boss Energy, CBA shares
• Experts name 3 ASX 200 shares to sell now
• Buy, hold, sell: Brambles, CBA, and Macquarie shares

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Morgans has given its verdict on a few popular ASX 200 stocks this week, courtesy of The Bull.

Let’s see how it rates them:

BHP Group Ltd (ASX: BHP)

Morgans is a fan of this mining giant. It likes its diversified operations, strong balance sheet, and disciplined capital management.

However, the main attraction appears to be copper, which the broker expects to be a key earnings driver thanks to the electrification megatrend.

However, given recent strength in BHP shares, Morgans thinks that they are fairly valued rather than offering a compelling buying opportunity. As a result, the broker has named BHP as a hold this week.

Commenting on its recommendation, Morgans said:

BHP provides diversified exposure to iron ore, copper and future-facing commodities, backed by a strong balance sheet and disciplined capital management. Copper offers long term appeal through electrification, while iron ore continues to drive near term earnings. However, results remain sensitive to global growth and Chinese demand.

With commodity prices reflecting mixed economic signals, BHP’s valuation looks fair rather than compelling. BHP suits investors seeking stability and income, but upside appears balanced by cyclical risk, supporting a hold rating.

Sigma Healthcare Ltd (ASX: SIG)

Morgans is far more positive on the investment opportunity with Sigma Healthcare shares.

It believes the Chemist Warehouse owner is well-placed to deliver margin improvement through own label expansion and exclusive products.

The broker also sees opportunities for the company to improve operating leverage with supply chain efficiencies and the consolidation of distribution centres following its merger.

So, with Sigma Healthcare shares trading closer to their 52-week low than their 52-week high, Morgans thinks now could be an opportune time to snap up shares. As a result, it has named the company as a buy this week.

Commenting on the opportunity, the broker said:

SIG is a leading wholesale distributor and retail pharmacy franchisor with operations in Australia, New Zealand, Ireland and the United Arab Emirates. It has a solid balance sheet with conservative leverage and strong operating cash flows. We believe SIG can continue to widen margins through expanding labels it owns and exclusive products.

We expect improving operating leverage through efficiencies in the supply chain and consolidation in distribution centres. A softer share price provides a compelling buying opportunity for long term focused investors.

The post Morgans says hold BHP shares and buy this ASX 200 stock       appeared first on The Motley Fool Australia.

More reading

• 3 ASX healthcare shares to buy amid sector rout: experts
• Buy, hold, sell: Sigma Healthcare, Macquarie, Santos shares
• How much could the BHP share price rise in the next year?
• Why I think these high-quality ASX shares deserve a spot in most investment portfolios
• Up 49% in a year, should you buy BHP shares for their ‘stability and income’?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have continued their downward momentum yet again in Tuesday afternoon trade.

At the time of writing, the beaten-down ASX biotech stock has fallen another 2.53% to $128.48, marking the lowest trading price since August 2017.

The shares are down 25% for the year to date and 47% lower than this time last year.

For context, the S&P/ASX 200 Index (ASX: XJO) is down 0.55% at the time of writing, and down 0.1% for the year to date. 

Why are CSL shares still falling?

ASX healthcare shares have lagged most other sectors on the index this year after a sharp, broad-based sell-off. 

Investors have shied away from healthcare shares this year and instead repositioned themselves towards ASX energy stocks, resources, and defensive assets. 

At the same time as a sector-wide sentiment shift, investors have also lost confidence in CSL as a business.

The biotech company was once widely regarded as one of the most dependable growth stocks on the ASX. But over the past few years, it has experienced a notable slowdown in earnings growth and operational challenges. More recently, CSL has faced headwinds such as lower vaccine demand, a surprise restructure, and even a shock CEO exit.

And the headwinds keep coming, too.

Earlier this month, CSL was hit by fresh policy changes out of the US. News that the US military has scrapped its annual flu shot requirement for service members significantly changes the demand outlook for CSL. The company generates a large portion of its revenue from the US, with its influenza vaccines forming part of that exposure.

Now investors are worried that lower vaccine uptake could weigh heavily on CSL’s future sales, especially in its segments where demand was driven by mandates.

Does this mean it’s time to sell my shares?

CSL shares are still struggling to stabilise, and confidence has been crushed. But I think that calling it quits on the biotech shares still looks premature.

While the company’s vaccine segment looks to be facing some new headwinds, it isn’t the core profit area for CSL. 

The bulk of CSL’s profits and earnings come from its plasma therapies division, CSL Behring. This segment includes plasma-derived medicines, including immunoglobulins, albumin, and clotting factors. The company’s blood plasma division dominates the market for rare blood disorders and immunoglobulin products. Demand in this sector is growing significantly. 

What do analysts expect next from CSL?

Analysts continue to be very bullish on the outlook for CSL shares. TradingView data shows that 12 of 18 analysts have a buy or strong buy rating on the stock, with an upside of up to 109% to $268.84 per share over the next 12 months.

Even the minimum $153.06 target price implies a 19% upside at the time of writing.

The post CSL shares crash to a 9-year low. Is it time to sell off my shares? appeared first on The Motley Fool Australia.

More reading

• Don’t sit out this ASX share market chaos, it could cost you
• Buy, hold, sell: Cochlear, CSL, and DroneShield shares
• The Warren Buffett rule I keep coming back to with ASX shares
• Down 50%, why I’d invest $20,000 into CSL shares
• 3 ASX shares I’d buy if the market dropped again

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in small-cap biotech Orthocell (ASX: OCC) edged higher today (around 4% at the time of writing) after the company released a clinical update that could prove more important than the market initially realised.

At the centre of the announcement is Remplir, Orthocell’s nerve repair product, which continues to deliver strong clinical outcomes.

Strong treatment success rate

Orthocell reported an overall treatment success rate of 89.7% across 66 patients and 78 procedures, based on its ongoing real-world evidence study. That’s a strong headline number with solid supporting evidence.

In motor nerve repair procedures, more than 90% of procedures resulted in functional muscle recovery. Meanwhile, in nerve decompression procedures (which are typically used to treat chronic pain, numbness, and tingling) 89% of patients experienced significant improvement or complete relief.

Importantly, these results were achieved across a broad patient group, covering different types of nerve injuries and age ranges. That kind of consistency suggests the product’s effectiveness isn’t limited to narrow use cases.

Just as critical is the safety profile. The study reported no post-treatment complications or adverse effects, reinforcing confidence for surgeons considering adoption.

Why this matters

For investors the focus is on what this means commercially.

Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir. Early traction is also building in the US, including procedures within a Department of Defense hospital network.

These are all emerging signs of real value being created which can hopefully translate into repeat usage, broader adoption, and ultimately, strong revenue growth.

Orthocell is now pushing into larger markets, with US expansion underway and Europe and the UK firmly in its sights. Regulatory approval in those regions is targeted for 2026, which could significantly expand its addressable market.

If the current clinical outcomes continue to hold and surgeon adoption keeps building, Orthocell may be moving closer to that key inflection point where a promising product becomes a scalable commercial business.

Foolish bottomline

Orthocell’s latest update strengthens the case that Remplir can be widely adopted. For investors, that’s a critical datapoint and if momentum continues, this could be the early stages of a much larger growth story.

The post This ASX biotech hit a 90% success rate. Can it unlock commercial growth? appeared first on The Motley Fool Australia.

More reading

• Are Orthocell shares a buy after crashing 7% yesterday?
• Orthocell caps 26% surge this week with first US Military Surgery
• Orthocell shares soar 22% on landmark US breakthrough

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are searching for ASX bank shares to buy, then read on.

That’s because analysts have named one to buy and two to sell this week, courtesy of The Bull.

Here’s what they are recommending:

Commonwealth Bank of Australia (ASX: CBA)

Analysts at Morgans are bearish on CBA shares and have named them as a sell this week.

The broker has concerns over its valuation and believes there are better opportunities elsewhere. It said:

CBA is Australia’s strongest major bank, with a leading retail franchise and consistent profitability. However, the market fully recognises these strengths. The shares were recently trading at a significant premium, leaving limited upside as interest rate benefits fade and competition increases. While the business remains high quality, future returns are likely to be more modest, in our view. With the company’s valuation pricing in a lot of good news, we see better value elsewhere, supporting a sell view.

Westpac Banking Corp (ASX: WBC)

Morgans is also recommending Westpac shares as a sell this week.

While the broker has been pleased with its business simplification progress, it isn’t enough to justify a more positive stance. This is especially the case given how growth drivers are limited in the current environment. It explains:

Westpac has made progress simplifying its business, but returns continue to lag peers. Growing revenue is a challenge in a competitive and mature banking market, while execution risk persists. Cost control and balance sheet strength offer some support, but growth drivers are limited in a slowing credit environment. The valuation doesn’t offer a clear margin of safety given these challenges. Income may appeal to some investors.

Macquarie Group Ltd (ASX: MQG)

One ASX share that is in favour is investment bank Macquarie. MPC Markets has named it as a buy this week.

It likes the company due to its strong track record and potential to outperform in the volatile markets we are experiencing at present. It said:

This global financial services company operates in more than 30 markets. Businesses include asset management, banking and financial services and commodity and global markets. Its diversification appeals to investors, particularly in volatile markets.

The trading desk has been a driver of growth in previous years and we suspect it will feature prominently at the company’s full year results due in May. The shares have surged from $191.53 on March 4 to trade at $229.95 on April 23. We believe the company’s outlook is bright. The company’s solid track record has stood the test of time.

The post Experts name 1 ASX bank share to buy and 2 to sell        appeared first on The Motley Fool Australia.

More reading

• Which of the big four bank shares has the most upside?
• Buy, hold, sell: Sigma Healthcare, Macquarie, Santos shares
• Buy, hold, sell: Macquarie, Boss Energy, CBA shares
• Buy, hold, sell: Goodman Group, BHP, Westpac shares
• Experts name 3 ASX 200 shares to sell now

Fetching Disclosure…

AML3D Ltd (ASX: AL3) shares are falling with the market on Tuesday.

At the time of writing, the ASX defence stock is down 2.5% to 20 cents.

The good news is that Bell Potter believes this could have created an incredible buying opportunity for investors.

In fact, the broker thinks that the 3D printing technology company’s shares could double in value from current levels.

What is Bell Potter saying about this ASX defence stock?

Bell Potter notes that the company released its third-quarter update earlier this week and revealed that momentum continues to build. It said:

AL3 continues to build momentum across installed capacity, system sales and parts manufacturing. An additional $12.5m in orders were placed during Q3 FY26 resulting in $20m orders year-to-date and on top of $9m in orders on hand at the beginning of FY26. Quarterly order additions included a Newport News Shipbuilding order of $9.9m for 4 ARCEMY systems and the US Navy $2.6m order for submarine components. AL3 is continuing its investments to double capacity in the US, grow its UK-Europe presence and continue its research and development push in Australia.

The broker highlights that demand for its systems from the US Navy will be key and was pleased with a recent appointment to support that relationship. It adds:

AL3 recently appointed a new US defence advisor Larissa Smith, former Director of Additive Manufacturing for the US Navy. In July 2025, AL3 announced receipt of a Letter of Intent from the US Navy which identified its Wire Additive Manufacturing technology as critical to meet demand and forecast the need for 100 WAM system installations. The LOI also identified around 400 components for the US Navy Maritime Industrial Base capable of being produced by WAM technology in 2026, increasing to 1,600 components by 2030.

Potential to double

According to the note, the broker has retained its speculative buy rating and 40 cents price target on the ASX defence stock. This is double its current share price of 20 cents.

Commenting on its recommendation, Bell Potter said:

AL3’s technology is particularly suited to maritime applications, giving it strong leverage into demand growth from the US Navy’s Maritime Industrial Base and the US SHIPS Act. Over FY26-27, we expect AL3 to increase deployment of ARCEMY systems to the US and Europe, increase prototyping activity and ultimately commence commercial scale production of components.

There is potential for the Navy LOI to expand beyond the Maritime Industrial Base to land-based assets. AL3 will also look to deploy its technology into non-defence sector industrial manufacturing.

The post Why Bell Potter says this ASX defence stock could rocket 100% appeared first on The Motley Fool Australia.

More reading

• Is this ASX defence stock the next DroneShield?
• 2 ASX small-cap shares Bell Potter says can race 30-100% higher

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Clinuvel Pharmaceuticals (ASX: CUV) rose around 3% after the company provided an update on its plans to uplist to the US based Nasdaq stock exchange.

The Nasdaq is the second largest stock exchange in the world (after the New York Stock Exchange) and one that has a reputation for providing a platform for some of the world’s most innovative companies including NVIDIA (NASDAQ: NVDA), Alphabet (NASDAQ: GOOG / GOOGL) and Microsoft (NASDAQ: MSFT).

A step closer to the US market

Clinuvel confirmed it is continuing discussions with the US Securities and Exchange Commission (SEC) as part of its plan to upgrade its American Depository Receipt (ADR) program from Level I to Level II and list on the Nasdaq.

The company has already gone through multiple rounds of feedback with the SEC and expects the review process to conclude before the end of the 2026 financial year. If successful, Clinuvel would trade on the Nasdaq under a new ticker, opening the door to a deeper pool of institutional capital.

Why this matters

A Nasdaq listing gives greater visibility, liquidity, and provides access to specialist healthcare investors who are often more familiar with biotech business models.

In a sector where funding and sentiment often go hand in hand, that visibility can be valuable for Clinuvel in the event of future capital raises.

Still, investors should keep expectations grounded. Firstly, uplisting alone doesn’t change the business fundamentals overnight, the company still needs to bring its vision to life with strong execution.

Secondly, it’s not a done deal. The company was clear that the process remains subject to regulatory approval and there is no guarantee the uplisting will proceed or occur within the expected timeframe.

Foolish bottom line

Clinuvel has a commercial product in SCENESSE®, which is approved in multiple markets including the US and Europe. The next phase of its story includes greater commercialisation and expanding its investor base.

A Nasdaq listing could elevate the company’s profile and open new doors, but strong business execution is still required.

After all, despite today’s modest gain, the stock is still down around 27% year to date. It’s a reminder that sentiment can shift quickly, and that investors are still waiting for a clearer growth narrative to emerge.

The post This ASX biotech is pushing for a Nasdaq listing. Could it reignite investor interest? appeared first on The Motley Fool Australia.

More reading

• Guess which ASX 300 stock was given a big boost from the US FDA
• How to generate monthly income using ASX ETFs
• Global investing is easy on the ASX with these ETFs
• Are these the best ASX ETFs to buy with $1,000 in May?
• 5 ASX ETFs that could supercharge your portfolio

Motley Fool contributor Kevin Gandiya has positions in NVIDIA, Alphabet and Microsoft. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Microsoft, and Nvidia. The Motley Fool Australia has recommended Alphabet, Microsoft, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are 0.5% lower as the market endures its sixth consecutive session in the red.

Despite volatile market conditions in 2026, brokers have signalled growing confidence in three ASX 200 shares this month.

The following stocks have just been upgraded to consensus strong buy ratings by the experts.

Let’s check them out.

Life360 Inc (ASX: 360)

The Life360 share price is $20.28, down 3.8% today.

Over the past six months, this ASX 200 tech share has lost 59% of its market valuation.

The substantial decline came amid a broader tech sector rout that ran from late August to 30 March this year.

Since the turnaround began on 31 March, Life360 shares have risen 11.8%.

Life360 was elevated to a consensus strong buy rating on the CommSec platform last week.

Bell Potter has a buy rating on Life360, with analyst Christopher Watt commenting (courtesy The Bull):

The company offers a compelling growth story driven by its unique position at the intersection of safety, connectivity and subscription-based monetisation.

The integration of hardware and software ecosystems provide options for further monetisation, while operating leverage is beginning to emerge.

Given strong top line momentum, expanding margins and the recent sell-off in line with the broader technology sector, Life360 presents an attractive risk-reward profile, particularly at current levels.

Bell Potter has a 12-month price target of $35.50 on Life360 shares. This implies a potential 75% capital gain ahead.

Capstone Copper Corp CDI (ASX: CSC)

The Capstone Copper share price is $11.80, down 1% today.

In the year to date (YTD), this ASX 200 copper share has fallen 19%.

Capstone Copper reached a consensus strong buy rating on CommSec earlier this month.

Morgans is buy-rated on Capstone Copper shares but trimmed its price target from $16 to $15.40 this month.

This still implies a potential 31% upside ahead.

In a note, Morgans says:

We have adjusted our CY26 production forecasts to better reflect the phasing of maintenance across assets and a revised production mix between cathode and sulphide output at Mantos Blancos and Mantoverde.

Net these changes our target price moves to A$15.40ps (previously A$16ps) and we maintain our BUY rating.

Genesis Minerals Ltd (ASX: GMD)

The Genesis Minerals share price is $6.31, down 1.8% today.

In the YTD, this ASX 200 gold share has fallen 14% while the value of the yellow metal has risen 8.7%.

Genesis Minerals reached a consensus strong buy rating on CommSec earlier this month.

Bell Potter is buy rated with a 12-month share price target of $9.90.

This implies a potential 57% capital gain ahead.

In a new note this month, the broker said:

We see GMD as undervalued relative to peers, with significant growth potential.

The 3Q result demonstrated cost discipline in a challenging environment.

The post 3 ASX 200 shares just upgraded to strong buy — here’s what the brokers are saying appeared first on The Motley Fool Australia.

More reading

• ASX 200 falls to a fresh 3-week low. Here’s what’s driving the sell-off today
• This ASX gold stock just smashed records, so why is it down?
• Greatland Resources posts record March quarter cash build and gold-copper resource growth
• Beach Energy lifts production in Q3 FY26, updates outlook
• Reliance Worldwide resets FY26 outlook, updates on tariffs and Middle East

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Australian investors now have $329 billion invested in ASX exchange-traded funds (ETFs), and March was the third-biggest month for net inflows ever.

It seems that the metals rout in January, and the global fuel crisis sparked by the war in Iran, has not dampened investors’ enthusiasm.

Here are two ASX ETFs that are outperforming amid volatile market conditions in 2026.

Betashares Crude Oil Index Currency Hedged Complex ETF (ASX: OOO)

The ASX OOO is $9.59 apiece, up 1.1% today and up 88.4% in the year to date (YTD).

This ASX ETF has shot the lights out due to skyrocketing oil prices as a result of the Iran war and the shutdown of the Strait of Hormuz.

The world’s benchmark oil price, Brent Crude, is now trading 78% higher in the YTD at US$109.38 per barrel today.

Meantime, West Texas Intermediate oil is up 68% in the YTD at US$97.46 per barrel on Tuesday.

This ASX ETF aims to track the S&P GSCI Crude Oil Index Excess Return, hedged against AUD/USD currency movements.

This gives investors exposure to WTI crude oil futures, rather than the spot price.

Betashares explains:

The price of oil futures contracts is not the same as the “spot price” of oil. As such, OOO does not aim to, and should not be expected to, provide the same return as the performance of this spot price.

The performance of an ETF that is linked to oil futures may be materially different to the performance of the spot price of oil itself.

This is because the process of “rolling” from one futures contract to the next to maintain investment exposure can result in either a cost or benefit to the Fund, affecting returns.

OOO ETF is backed by cash, which is held in bank accounts with a third-party custodian on behalf of investors.

Global X Semiconductor ETF (ASX: SEMI)

The ASX SEMI is $32.08 apiece, down 1% today and up 37% in the YTD.

This ASX ETF is riding the wave of the artificial intelligence (AI) revolution playing out worldwide today.

Semiconductors are essential for controlling electrical currents in devices like computer chips and smartphones.

They are especially critical for AI because they power the high-performance processors and memory needed to train and run advanced AI models quickly and efficiently.

SEMI ETF tracks the Solactive Global Semiconductor 30 Index. As the name suggests, there are just 30 shares within this index.

The world’s biggest semiconductor manufacturer, Taiwan Semiconductor Manufacturing Company, and semiconductor designers Broadcom and Nvidia Corp are SEMI ETF’s three largest holdings.

Together, they represent 27% of the ASX ETF’s total investments.

This ASX ETF began trading in 2021 and has $773 million in funds under management today.

The post 2 ASX ETFs up 35% or more in 2026 appeared first on The Motley Fool Australia.

More reading

• 3 of the best performing thematic ASX ETFs over the last 3 years
• How to invest in the AI Build-Out: Expert
• 5 thematics driving ASX ETF investment today: expert
• What were the best performing Betashares ASX ETFs in March?
• Why is this ASX ETF up nearly 50% in a month?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is in the red in Tuesday morning trade, down another 0.54%. If the index keeps tumbling it’ll mark six straight days of declines.

The Australian share market has seen widespread selling across most sectors and weak investor sentiment. The ASX 200 is also reacting to a mixed start in US sharemarkets this week.

The softer market has also seen some ASX 200 shares fall to fresh 52-week lows.

Here are four of them.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Fisher & Paykel shares are down another 0.24% this morning to a new 52-week low of $29.18 a piece. The slump means the respiratory designer and manufacturer’s share price is now 10% lower for the year-to-date and 9% lower than this time last year. There hasn’t been any price-sentitive news out of the company recently to explain the decline, so it’s most likely the result of a continued sector-side sell off of ASX healthcare shares. TradingView data suggests brokers are still bullish for the ASX 200 company’s shares, with the majority holding a buy or strong buy rating on the stock. Brokers tip an average 20% upside to $34.86 over the next 12 months.

Ansell Ltd (ASX: ANN)

Ansell is another ASX 200 healthcare company which makes gloves and other personal protection equipment. Its shares have also been caught up in the widespread ASX healthcare sell-off. At the time of writing, Ansell shares are down 1.06% to $26.24 a piece, marking a 22-month low. Again, brokers are bullish about the outlook for the ASX 200 company’s shares. Out of 12 analysts, seven have a hold rating and 5 rate the shares a buy or strong buy. Brokers tip an average 34% upside to $35.18 over the next 12 months. Some think the shares can rocket even further. The maximum $40.45 target price implies a potential 54% upside at the time of writing.

Harvey Norman Holdings Ltd (ASX: HVN)

Harvey Norman shares have hit a fresh 52-week low of $4.47 in Tuesday morning trade. The share price has now crashed 36% for the year-to-date after the sell-off accelerated in late-February. The ASX 200 retail giant has faced strong headwinds over the past year on the back of renewed concerns about rising inflation and how it could impact consumer spending. Tighter household budgets mean Australians are spending less on discretionary items this year. At the same time, after a strong rally in mid-late 2025, it looks like investors quickly took their profits off the table in early 2026. TradingView data shows that analysts are relatively divided about the outlook or the shares, with several neutral ratings, but they mostly agree that the shares are now trading below fair value. The average target price on the ASX 200 retail shares is $5.76, which implies another 29% upside at the time of writing. 

Metcash Ltd (ASX: MTS)

Metcash shares have tumbled another 1.42% in morning trade to a new 52-week low of $2.78 a piece. It also represents the lowest point the shares have fallen to in nearly six years. The IGA network owner’s shares have come under pressure following an underwhelming FY26 half-year result in December last year. It continues to face headwinds amid a tough retail environment and dwindling demand in its tobacco and liquor businesses. Analysts are mostly neutral on the outlook for the shares, but they do all agree that there will be some level of upside ahead. The average target price of $3.44 implies a potential 23% upside over the next 12 months, at the time of writing. 

The post These 4 ASX 200 shares have slumped to fresh 52-week lows: Buy, sell or hold? appeared first on The Motley Fool Australia.

More reading

• How much could a $50,000 ASX share portfolio pay in dividends?
• Nervous investors turn to ASX 200 defensives as global energy shock drags on
• 100,720 shares of this high-yield ASX dividend stock pay income equal to the Age Pension
• Almost ready to retire? I’d buy cheap ASX dividend shares for passive income
• Down 40%: These high-yield ASX dividend shares are rated as buys

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.